secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLIGENIX, INC. (SNGX)
CIK:        0000812796
Form:       8-K
Filed at:   2022-12-15T23:59:59+00:00
Accession:  0001558370-22-018677
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soligenix submits NDA to FDA for HyBryte in cutaneous T-cell lymphoma; targets H2 2023 approval
--------------------------------------------------------------------------------

- NDA submitted for HyBryte (synthetic hypericin) to treat early stage CTCL, a rare cancer affecting >25,000 US patients.
- NDA has FDA orphan drug and fast track designations; company anticipates potential approval in H2 2023.
- Company estimates worldwide market for HyBryte in CTCL at over $250 million.
- US launch targeted for Q1 2024, contingent upon FDA approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/812796/000155837022018677/0001558370-22-018677-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/812796/000155837022018677/tmb-20221215x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-018677

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer